

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

UNNATURAL ENANTIOMERS OF 5-AZACYTIDINE ANALOGUES: SYNTHESSES AND ENZYMATIC PROPERTIES

G. Gaubert^a; G. Gosselin^a; S. Eriksson^b; A. Vita^c; G. Maury^a

^a UMR 5625 du CNRS, Département de Chimie, Université Montpellier II, Montpellier, Cedex 5, France

^b Department of Veterinary Medical Chemistry, the Biomedical Centre, Box 575, Swedish University of Agricultural Sciences, Uppsala, Sweden ^c Dipartimento di Scienze Veterinarie, Università di Camerino, maica, Italy

Online publication date: 31 March 2001

To cite this Article Gaubert, G. , Gosselin, G. , Eriksson, S. , Vita, A. and Maury, G.(2001) 'UNNATURAL ENANTIOMERS OF 5-AZACYTIDINE ANALOGUES: SYNTHESSES AND ENZYMATIC PROPERTIES', *Nucleosides, Nucleotides and Nucleic Acids*, 20: 4, 837 – 840

To link to this Article: DOI: 10.1081/NCN-100002441

URL: <http://dx.doi.org/10.1081/NCN-100002441>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

UNNATURAL ENANTIOMERS OF 5-AZACYTIDINE ANALOGUES: SYNTHESSES AND ENZYMATIC PROPERTIES

G. Gaubert,¹ G. Gosselin,¹ S. Eriksson,² A. Vita,³
and G. Maury^{1,*}

¹UMR 5625 du CNRS, Département de Chimie, Université Montpellier II,
Place Bataillon, 34095 Montpellier Cedex 5, France

²Swedish University of Agricultural Sciences, Department of Veterinary
Medical Chemistry, the Biomedical Centre, Box 575,
S-75123 Uppsala, Sweden


³Dipartimento di Scienze Veterinarie, Università di Camerino,
62024 Matelica, Italy

ABSTRACT

2'-Deoxy- β -L-5-azacytidine (L-Decitabine), β -L-5-azacytidine, and derivatives were stereospecifically prepared starting from L-ribose or L-xylose. D- and L-enantiomers of 2'-deoxy- β -5-azacytidine were weak substrates of human recombinant deoxycytidine kinase (dCK), whereas both enantiomers of β -5-azacytidine or the L-xylo-analogues were not substrates of the enzyme. None of the reported derivatives of β -L-5-azacytidine was a substrate of human recombinant cytidine deaminase (CDA).

β -D-5-Azacytidine (β -D-5-azaC), **1**, and 2'-deoxy- β -D-5-azacytidine (β -D-5-azadC, Decitabine), **2**, are important antileukemic agents used in clinical treatment [1,2]. The use of β -D-5-azaC or β -D-5-azadC suffers however from several drawbacks. The inclusion of an extra nitrogen atom into the cytosine base increases its chemical sensitivity with respect to nucleophiles and accounts for the instability of the compounds in aqueous solution [3]. Another major cause of resistance is

*Corresponding author.



- 1** ($R_1 = R_3 = H, R_2 = R_4 = OH$) **3** ($R_1 = R_3 = H, R_2 = R_4 = OH$)
2 ($R_1 = R_2 = R_3 = H, R_4 = OH$) **4** ($R_1 = R_2 = R_3 = H, R_4 = OH$)
5 ($R_1 = R_4 = H, R_2 = R_3 = OH$)
6 ($R_1 = R_2 = R_4 = H, R_3 = OH$)

Figure 1. β -D- and β -L-5-azacytidine analogs studied as substrates of human dCK and human CDA.

induced by the ubiquitous cellular enzyme cytidine deaminase (CDA) since deamination of **1** or **2** results in total loss of activity [4,5]. We have previously shown that a number of cytidine analogues having the unnatural L stereochemistry are both substrates of human deoxycytidine kinase (dCK) and resistant to human cytidine deaminase [6]. We therefore stereospecifically prepared the L-enantiomers of **1**, **2** and other analogues (Fig. 1), and we studied their enzymatic properties with respect to dCK and CDA in the hope of getting phosphorylation, a lack of deamination of these compounds and possibly an efficient incorporation into DNA.

Chemistry

Most previous syntheses of 5-azacytidine analogues yield both α - and β -anomers often difficult to separate. For this reason, we used regio- and stereospecific methods to prepare the L-enantiomers **3–6** starting from L-ribose or L-xylose (Fig. 1). 1-*O*-Acetyl-2,3,5-tri-*O*-benzoyl- β -L-ribofuranose was coupled with silylated 5-azacytidine in the presence of trimethylsilyltriflate. The 2'-benzoyl group controls the stereochemistry of the substitution [7] and only the β -anomeric derivative was obtained. Deprotection catalysed by sodium methanolate in methanol afforded β -L-ribofuranosyl-5-azacytosine, **3**, in good yield. The 3'- and 5'-positions of **3** were then protected using dichlorotetraiso-propyldisiloxane. A Barton-McCombie elimination of the 2'-hydroxyl group of the 3',5'-diprotected compound followed by deprotection gave L-Decitabine, **4**, in 42% overall yield from **3**. 1,2-Di-*O*-acetyl-3,5-di-*O*-benzoyl-L-xylo-furanose was similarly condensed with silylated 5-azacytosine giving exclusively the β -anomeric derivative. Deprotection with sodium



methanolate afforded β -L-xylofuranosyl-5-azacytosine, **5**, whereas deacetylation followed by a Barton-McCombie elimination of the 2'-hydroxyl group and debenzoylation yielded 2'-deoxy- β -L-*threo*-pentofuranosyl-5-azacytosine, **6**.

Biological Results and Discussion

Several studies of the action of dCK on **1** and **2** have been previously reported, and evaluations of the substrate character of β -D-5-azaC with respect to dCK have shown that it is either low or non-existent [8]. Concerning β -D-5-azadC (Decitabine), all existing studies indicate that this compound is an average substrate of human or mammal dCK, with K_m ranging from 29 to 71 μ M depending on the origin of the enzyme and on the conditions [9,10]. We used HPLC to follow the kinetics of phosphorylation of **1–6** in the presence of human dCK. Under our conditions, substrate reversible decomposition was held below 2% for the duration of the kinetics. With 5 mM ATP as phosphate donor, only 2'-deoxy- β -D-5-azacytidine, **2**, and 2'-deoxy- β -L-5-azacytidine, **4**, were phosphorylated (K_m : 94 and 17 μ M, respectively). The efficiencies of phosphorylation were similar for the two enantiomers (V_m/K_m : 0.075 and 0.05, respectively, compared to 2'-deoxy- β -D-cytidine). The value of the K_m constant for 2'-deoxy- β -D-5-azacytidine is similar to the constants previously determined [9,10]. In contrast, no phosphorylation was observed in the case of both enantiomers of β -5-azacytidine, **1** and **3**. The β -L-xylo- or 2'-deoxy-xylo-derivatives **5** and **6** did not display any substrate properties.

Numerous studies have evaluated the sensitivity of β -D-5-azacytidine and 2'-deoxy- β -D-5-azacytidine to deamination catalysed by cytidine deaminase [11,12]. Using a low temperature (25°C) and short kinetic durations allowed us to limit the decomposition of the substrates as observed from HPLC analysis. Only the D-enantiomers **1** and **2** were substrates of human CDA (K_m values 225 and 690 μ M, respectively) whereas no deamination occurred for the L-enantiomers **3–6**, under the same conditions and in the presence of increased concentrations of enzyme.

The prepared L-nucleoside analogues **3–6** were tested as inhibitors of HIV replication in CEM-SS and MT-4 cell systems or as inhibitors of HBV replication in HepG2 cells following standard protocols. None of the compounds displayed any significant antiviral or cytotoxic effect. Our study only shows that L-Decitabine may be monophosphorylated in cells and is resistant to enzymatic deamination. The substrate properties and enantioselectivities of cellular nucleotide kinases, viral DNA polymerases or other concerned enzymes with respect to the reported compounds are not known and could be unfavourable.

REFERENCES

1. Sorm, F.; Vesely, J. *Neoplasma* **1968**, *15*, 339–343.
2. Momparler, R.L.; Momparler, L.F.; Samson, J. *Leukemia Res.* **1984**, *8*, 1043–1049.
3. Pinto, A.; Zagonel, V. *Leukemia*, **1993**, *7 Suppl. Monograph 1*, 51–60.

© MARCEL DEKKER, INC.
270 Madison Avenue, New York, New York 10016



4. Momparler, R.L.; Côté, S.; Eliopoulos, N. *Leukemia*, **1997**, *11 Suppl. 1*, 1–6.
5. Laliberté, J.; Marquez, V.E.; Momparler, R.L. *Cancer Chemother. Pharmacol.* **1992**, *30*, 7–11.
6. Shafiee, M.; Griffon, J.-F.; Gosselin, G.; Cambi, A.; Vincenzetti, S.; Vita A.; Erikson, S.; Imbach, J.-L.; Maury, G. *Biochem. Pharmacol.* **1998**, *56*, 1237–1242.
7. Gaubert, G.; Gosselin, G.; Boudou, V.; Imbach, J.-L.; Eriksson, S.; Maury, G. *Biochimie* **1999**, *81*, 1041–1047.
8. Krenitsky, T.A.; Tuttle, J.V.; Koszalka, G.W.; Chen, I.S.; Beacham III, L.M.; Rideout, J.L.; Elion, G.B. *J. Biol. Chem.* **1976**, *251*, 4055–4061.
9. Momparler, R.L. *FEBS Symp.* **1979**, *57*, 33–41.
10. Vesely, J.; Cihak, A. *Neoplasma* **1980**, *27*, 121–127.
11. Chabot, G.G.; Bouchard, J.; Momparler, R.L. *Biochem. Pharmacol.* **1983**, *32*, 1327–1328.
12. Vincenzetti, S.; Cambi, A.; Neuhard, J.; Garattini, E.; Vita, A. *Protein Expression Purif.* **1996**, *8*, 247–253.



Request Permission or Order Reprints Instantly!

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

[Order now!](#)

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN100002441>